l*******2
发帖数: 1 | 1 这个公司有个独门技术，就是注射表达基因不需要病毒载体。
季博士打算拿来表达他的抗体。季博士学术基础深厚啊
https://www.fool.com/investing/2020/07/24/sorrento-therapeutics-to-buy-its-
coronavirus-vacci.aspx
Sorrento Therapeutics (NASDAQ:SRNE) made another committment toward
developing new COVID-19 treatments and vaccines on Friday. The company has
entered into a letter of intent to acquire privately held SmartPharm
Therapeutics and its pipeline of non-viral gene therapies. The deal is
expected to close next month; financial terms weren't disclosed.
Gene therapies generally rely on viral vectors to deliver genetic material,
but this procedure adds a thick layer of complexity to the manufacturing
process. Reactions are rare, but unexpected immune responses are another
issue for viral-vector technology. SmartPharm's approach involves delivering
strands of DNA and messenger RNA directly to cells with simple injections
that don't involve any viral vectors.
In March, Sorrento and SmartPharm began collaborating on injectable gene
therapies that lead to the production of antibodies originally discovered by
Sorrento to fight SARS-CoV-2, the virus that causes COVID-19.
The first candidate to enter clinical trials using SmartPharm's delivery
technology will most likely be based on STI-1499, which is currently miles
behind the front runners in the race to develop a coronavirus vaccine. The
company still hasn't submitted an investigational new drug application (IND)
for STI-1499 or the version to be encoded on a DNA plasmid injection called
STI-1499dpi.
An approved IND is a pre-requisite to begin clinical trials in the U.S., and
the company doesn't plan to submit an application until next month for STI-
1499. There's still no telling when STI-1499dpi will be ready for its first
human proof-of-concept trial. |
|
